DK0565634T3 - Angiotensin-II-receptorblokkersammensætninger - Google Patents

Angiotensin-II-receptorblokkersammensætninger

Info

Publication number: DK0565634T3
Authority: DK; Denmark
Prior art keywords: angiotensin; receptorblokkersammensætninger; blocker; diuretic; beta
Prior art date: 1990-12-14

Application number

DK92904382T

Other languages

Danish (da)

English (en)

Inventor

Joseph Weinstock

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-14

Filing date

1991-12-13

Publication date

1999-09-27

1991-12-13 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

1999-09-27 Application granted granted Critical

1999-09-27 Publication of DK0565634T3 publication Critical patent/DK0565634T3/da

Links

102000005862 Angiotensin II Human genes 0.000 title 1
101800000733 Angiotensin-2 Proteins 0.000 title 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title 1
229950006323 angiotensin ii Drugs 0.000 title 1
239000005541 ACE inhibitor Substances 0.000 abstract 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 abstract 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 abstract 1
229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 1
239000002876 beta blocker Substances 0.000 abstract 1
239000000480 calcium channel blocker Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000002461 renin inhibitor Substances 0.000 abstract 1
229940086526 renin-inhibitors Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Agronomy & Crop Science (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK92904382T 1990-12-14 1991-12-13 Angiotensin-II-receptorblokkersammensætninger DK0565634T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62880790A	1990-12-14	1990-12-14
PCT/US1991/009362 WO1992010097A1 (fr)	1990-12-14	1991-12-13	Compositions de blocage de recepteur de l'angiotensine ii

Publications (1)

Publication Number	Publication Date
DK0565634T3 true DK0565634T3 (da)	1999-09-27

Family

ID=24520386

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92904382T DK0565634T3 (da)	1990-12-14	1991-12-13	Angiotensin-II-receptorblokkersammensætninger

Country Status (13)

Country	Link
EP (1)	EP0565634B1 (fr)
JP (1)	JP3398379B2 (fr)
KR (1)	KR100222252B1 (fr)
AT (1)	ATE177634T1 (fr)
AU (1)	AU656551B2 (fr)
CA (1)	CA2098176C (fr)
DE (2)	DE69131021T2 (fr)
DK (1)	DK0565634T3 (fr)
ES (1)	ES2130170T3 (fr)
GR (1)	GR3030293T3 (fr)
LU (1)	LU91234I2 (fr)
NL (1)	NL300115I2 (fr)
WO (1)	WO1992010097A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5185351A (en) *	1989-06-14	1993-02-09	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ242724A (en) *	1991-05-15	1994-09-27	Du Pont	Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
GB9117361D0 (en) *	1991-08-12	1991-09-25	Euro Celtique Sa	Oral dosage form
CA2125251C (fr) *	1993-06-07	2005-04-26	Yoshiyuki Inada	Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
JP3057471B2 (ja)	1993-06-07	2000-06-26	武田薬品工業株式会社	アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5721263A (en)	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
EP0629408A1 (fr) *	1993-06-16	1994-12-21	LABORATOIRES MERCK, SHARP & DOHME-CHIBRET	Combination d'inhibiteurs ACE et d'antagonistes AII
CA2168066A1 (fr) *	1995-02-08	1996-08-09	James R. Powell	Traitement de l'hypertension et de l'insuffisance cardiaque globale
EP0835106A4 (fr) *	1995-06-30	1998-09-30	Merck & Co Inc	Procede de traitement de nephropathies a l'aide d'un inhibiteur de l'ace et d'un antagoniste de l'a ii
SI0914158T2 (sl)	1996-04-05	2006-04-30	Takeda Chemical Industries Ltd	Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost
US6087386A (en) *	1996-06-24	2000-07-11	Merck & Co., Inc.	Composition of enalapril and losartan
JP2000513356A (ja) *	1996-06-24	2000-10-10	メルクエンドカンパニーインコーポレーテッド	エナラプリルとロサルタンの組成物
KR100508044B1 (ko) *	1997-08-06	2005-08-17	스미스클라인 비참 코포레이션	에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법
US6204281B1 (en)	1998-07-10	2001-03-20	Novartis Ag	Method of treatment and pharmaceutical composition
KR100634953B1 (ko) *	1998-07-20	2006-10-17	스미스클라인 비참 코포레이션	에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제
CN101011390A (zh)	1999-01-26	2007-08-08	诺瓦提斯公司	血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6395728B2 (en)	1999-07-08	2002-05-28	Novartis Ag	Method of treatment and pharmaceutical composition
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP2335700A1 (fr)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
DK1507558T3 (da)	2002-05-17	2011-12-05	Novartis Pharma Ag	Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
TW200306799A (en) *	2002-05-17	2003-12-01	Novartis Ag	Combination of organic compounds
US20060013852A1 (en) *	2002-06-28	2006-01-19	Prescott Margaret F	Use of organic compounds
BRPI0406987A (pt)	2003-01-31	2006-01-10	Sankyo Co	Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
RS52931B (sr)	2004-02-20	2014-02-28	Boehringer Ingelheim International Gmbh	Inhibitori virusne polimeraze
JP2007527915A (ja) *	2004-03-08	2007-10-04	ワイス	イオンチャンネルモジュレーター
NZ586285A (en) *	2004-03-17	2011-12-22	Novartis Ag	Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
EP1750862B1 (fr)	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Composition pharmaceutique contenant de l'irbesartan
US7531560B2 (en)	2004-11-10	2009-05-12	Boehringer Ingelheim Pharmaceuticals, Inc.	Anti-cytokine heterocyclic compounds
DE102005031577A1 (de)	2005-07-06	2007-01-11	Bayer Healthcare Ag	Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
US20080261958A1 (en) *	2005-11-08	2008-10-23	Randy Lee Webb	Combination of Organic Compounds
CN101534798B (zh) *	2006-10-30	2012-02-15	韩诺生物制约株式会社	包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da)	2007-06-04	2012-11-05	Synergy Pharmaceuticals Inc	Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US20110111022A1 (en)	2008-04-10	2011-05-12	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation
EP2328910B1 (fr)	2008-06-04	2014-08-06	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AR073380A1 (es)	2008-09-25	2010-11-03	Takeda Pharmaceutical	Composicion farmaceutica solida. comprimido multicapa
DE102008059206A1 (de)	2008-11-27	2010-06-10	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
JP6231553B2 (ja)	2012-05-07	2017-11-15	バイエルファーマアクチエンゲゼルシャフト	ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法
US9486494B2 (en)	2013-03-15	2016-11-08	Synergy Pharmaceuticals, Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
JP6606491B2 (ja)	2013-06-05	2019-11-13	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338238C (fr) *	1988-01-07	1996-04-09	David John Carini	Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
ES2207091T3 (es) *	1989-06-14	2004-05-16	Smithkline Beecham Corporation	Acido imidazolil-alquenoico.
FR2681067B1 (fr) *	1991-09-10	1993-12-17	Elf Sanofi	Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
NZ237476A (en) *	1990-03-20	1994-01-26	Sanofi Sa	N-substituted heterocyclic compounds and pharmaceutical compositions.

1991
- 1991-12-13 KR KR1019930701810A patent/KR100222252B1/ko not_active Expired - Lifetime
- 1991-12-13 JP JP50431592A patent/JP3398379B2/ja not_active Expired - Lifetime
- 1991-12-13 ES ES92904382T patent/ES2130170T3/es not_active Expired - Lifetime
- 1991-12-13 CA CA002098176A patent/CA2098176C/fr not_active Expired - Lifetime
- 1991-12-13 AU AU91782/91A patent/AU656551B2/en not_active Expired
- 1991-12-13 DK DK92904382T patent/DK0565634T3/da active
- 1991-12-13 DE DE69131021T patent/DE69131021T2/de not_active Expired - Lifetime
- 1991-12-13 AT AT92904382T patent/ATE177634T1/de active
- 1991-12-13 WO PCT/US1991/009362 patent/WO1992010097A1/fr not_active Ceased
- 1991-12-13 DE DE1991631021 patent/DE10399008I1/de active Pending
- 1991-12-13 EP EP92904382A patent/EP0565634B1/fr not_active Expired - Lifetime
1999
- 1999-05-20 GR GR990401379T patent/GR3030293T3/el unknown
2003
- 2003-02-21 NL NL300115C patent/NL300115I2/nl unknown
2006
- 2006-04-12 LU LU91234C patent/LU91234I2/fr unknown

Also Published As

Publication number	Publication date
LU91234I2 (fr)	2006-06-12
EP0565634B1 (fr)	1999-03-17
ATE177634T1 (de)	1999-04-15
ES2130170T3 (es)	1999-07-01
NL300115I2 (nl)	2003-09-01
NL300115I1 (nl)	2003-05-01
EP0565634A4 (en)	1996-04-17
JPH06503834A (ja)	1994-04-28
CA2098176A1 (fr)	1992-06-14
CA2098176C (fr)	2006-12-12
GR3030293T3 (en)	1999-09-30
WO1992010097A1 (fr)	1992-06-25
AU656551B2 (en)	1995-02-09
AU9178291A (en)	1992-07-08
KR100222252B1 (ko)	1999-10-01
EP0565634A1 (fr)	1993-10-20
DE69131021D1 (de)	1999-04-22
JP3398379B2 (ja)	2003-04-21
DE10399008I1 (de)	2006-06-08
KR930702895A (ko)	1993-11-29
DE69131021T2 (de)	1999-08-12
HK1012209A1 (en)	1999-07-30

Publication	Publication Date	Title
DK0565634T3 (da)	1999-09-27	Angiotensin-II-receptorblokkersammensætninger
RU2012110522A (ru)	2013-09-27	Гипотензивная комбинация валсартана и блокатора кальциевых каналов
ES2149451T3 (es)	2000-11-01	Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido.
TR199900591T2 (xx)	1999-07-21	Geri ak�� nleyicileri.
ES2172657T3 (es)	2002-10-01	Inhibidores de trombina.
ES2178157T3 (es)	2002-12-16	Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
NO996352D0 (no)	1999-12-20	<Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus
PT97615A (pt)	1992-03-31	Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
EA200200503A1 (ru)	2002-12-26	Способ лечения ревматоидного артрита
BG102976A (en)	1999-08-31	Method for the preparation of drospyrenon (6 beta,7 beta: 15 beta,16 beta - dimethylene-3-oxo-17 alpha -pregn-4-ene-21,17-carbolacton, drsp)as well as 7 alpha-(3-hydroxy-1-propyl)-(6 beta,7 beta: 15 beta,16 beta -dirmethylene-5 beta-androstan-3 beta,5,17 beta -triol (zk 92836) and (6 beta,7 beta: 15 beta,16 beta - dimethylene-5 beta-hydroxy-3-oxo-17 alpha -androstan-21, 17-carbolacton (90965) as intermediate compounds of the method
DK0805812T3 (da)	2001-09-17	Bicyklisk substitueret hexahydrobenz[e]isoindol som alfa-1-adrenerge antagonister
IL70882A0 (en)	1984-05-31	Certain benzazocinone and benzazoninone derivatives
ES2191830T3 (es)	2003-09-16	Inhibidores de trombina.
AU8534291A (en)	1992-03-02	Renal-selective angiotensin ii antagonists for treatment of hypertension
BR9809848A (pt)	2000-06-27	Composição
AU6187898A (en)	1998-08-25	Method for preventing or treating low renin hypertension by administering an endothelin antagonist
ES2175437T3 (es)	2002-11-16	Composicion de enalapril y losartan.
ATA156496A (de)	1997-10-15	Pharmazeutische zusammensetzung
AR011730A1 (es)	2000-08-30	UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA
EA199800533A1 (ru)	1999-02-25	Композиция для лечения боли
IL130642A0 (en)	2000-06-01	N-(pyridinylamino)isoindolines and related compounds
NO981188D0 (no)	1998-03-17	5-HT3-reseptorantagonister for dyskinesi